Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N, Curran WJ Jr. Murray KJ, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):453-9. doi: 10.1016/0360-3016(95)93160-9. Int J Radiat Oncol Biol Phys. 1995. PMID: 7852106 Free article. Clinical Trial.
Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV. Lawton CA, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):931-9. doi: 10.1016/s0360-3016(97)00288-5. Int J Radiat Oncol Biol Phys. 1997. PMID: 9276357 Clinical Trial.
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM; Radiation Therapy Oncology Group Protocol 92-02. Valicenti RK, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. doi: 10.1016/j.ijrobp.2006.06.017. Epub 2006 Sep 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979837
Postoperative radiation for cervical cancer with pathologic risk factors.
Hart K, Han I, Deppe G, Malviya V, Malone J Jr, Christensen C, Chuba P, Porter A. Hart K, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):833-8. doi: 10.1016/s0360-3016(96)00560-3. Int J Radiat Oncol Biol Phys. 1997. PMID: 9128959
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, et al. Porter AT, et al. Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805-13. doi: 10.1016/0360-3016(93)90309-j. Int J Radiat Oncol Biol Phys. 1993. PMID: 8478230 Clinical Trial.
1,830 results